Diaceutics - FY22 Trading Update - Jan 2023
FY22 has proven to be a great year for Diaceutics, which comfortably beat revenue expectations and maintained its EBITDA margin in the face of a transitioning business model and a highly inflationary world. It has also announced a key strategic update as well as new enterprise level agreements with two “top 10 global pharma companies”. We detail these later in the note, but together they represent $7m of data subscription agreements over 2 years, which to us further highlights the success of the conversion of this business to a platform-based subscription model.
Capital Access Group advises companies on effective engagement with investors. Our experienced team offers market-leading access with hard-to-reach investors, including smaller institutions, pension funds and private client fund managers. These under-serviced investors are located not only in London but across the regions of the UK and Europe. We have an unrivalled knowledge of this extensive audience, to whom our published research is distributed, as well as to larger institutions. We offer this service as part of an integrated investor communications strategy to promote a company’s investment story.
Our clients, ranging from AIM to FTSE 100 companies, benefit from our professional, long-term relationships with investors. Not only do we identify and target investors, we contact them directly and relay their views back to clients with analysis, interpretation and advice. This ensures that our clients are in control of their investor engagement. The objective is to improve the reach and engagement with investors, which in turn strengthens the share price.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.